Coronavirus: WHO declines comment on remdesivir in COVID-19, hopes for best

Executive Director of WHO emergencies program Mike Ryan speaks at a news conference on the novel coronavirus in Geneva, Switzerland February 6, 2020. (Reuters)

A top World Health Organization official declined comment on Wednesday on reports that Gilead Science’s remdesivir could help treat COVID-19, the respiratory disease caused by the novel coronavirus, but said that further data was needed.

“I wouldn’t like to make any specific comment on that, because I haven’t read those publications in detail,” Dr Mike Ryan, head of the WHO’s emergencies program, told an online briefing in response to a question, adding it can sometimes take a number of publications to determine a drug’s efficacy.

Read the latest updates in our dedicated coronavirus section.

“Clearly we have the randomized control trials that are underway both in the UK and US, the ‘Solidarity trials’ with WHO. Remdesivir is one of the drugs under observation in many of those trials. So I think a lot more data will come out,” he said.

Ryan added: “But we are hopeful this drug and others may prove to be helpful in treating COVID-19.”

Two ampules of Ebola drug remdesivir. (File photo: Reuters)

Two ampules of Ebola drug remdesivir. (File photo: Reuters)

Read more:

Coronavirus: WHO says it acted ‘quickly and decisively’

US says China labs working on contagious pathogens, unsure of adequate security

Remdesivir showed ‘no significant benefit’ in coronavirus patients

SHOW MORE
Last Update: Wednesday, 20 May 2020 KSA 10:02 - GMT 07:02
Top